Immuneering Corporation (IMRX) AI Stock Analysis

Immuneering Corporation, headquartered in Cambridge, Massachusetts, specializes in advancing product candidates primarily within oncology and neuroscience. Its pipeline is anchored by lead candidate IMM-1-104, a dual-MEK inhibitor targeting pancreatic, melanoma, colorectal, and non-small cell lung cancers driven by RAS and RAF gene mutations. It is also developing IMM-6-415 for solid tumors. In addition, the firm is pursuing five discovery-stage oncology programs targeting the MAPK and mTOR signaling pathways, alongside two discovery-stage neuroscience programs. Founded in 2008 as a subsidiary of Teva Pharmaceutical Industries Limited, the company now operates as an independent entity.

Immuneering generated revenue of $1.9M in FY2019 and $2.3M in FY2020 before revenue declined to $2.1M in FY2021, $316,952 in FY2022, and $455 in FY2023, representing a 4-year revenue CAGR of -87.6%. R&D expense increased from $4.3M in FY2019 to $41.6M in FY2023. Annual net income widened from -$7.7M in FY2019 to -$53.5M in FY2023, with FY2023 EPS at -$1.89 compared to -$3.76 in FY2021. For the trailing twelve months ended June 30, 2026, revenue stood at $455 with a quarterly revenue growth decline of 99.8% year-over-year, while EPS was -$0.93.

As of June 30, 2026, Immuneering reported $149.9M in cash and short-term investments and total debt of $3.6M, resulting in net cash of $146.3M. Total assets were $202.1M against shareholders' equity of $190.7M, yielding a current ratio of 19.47 and a debt-to-equity ratio of 0.02. Operating cash flow in FY2023 was -$49.0M, and free cash flow was -$49.3M. In FY2025, capital expenditures were $142,226, while the 5-year share count change was 149.1%.

Immuneering holds a market capitalization of $232.3M and an enterprise value of $137.8M. The stock trades at a price-to-sales ratio of 563.6x and a price-to-book ratio of 1.5x, compared to a median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. Over the past year, the stock declined 35.2%, underperforming the 16.8% return of the S&P 500. Over a 5-year timeframe, the stock declined 85.6% versus an 83.0% gain for the S&P 500.

Immuneering has consensus coverage consisting of 5 Strong Buy and 2 Buy ratings, with zero Hold, Sell, or Strong Sell ratings. The mean price target is $17.17, representing a 378.2% premium over the last close of $3.59 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate revenue of $0 and an EPS of -$1.12. For the following fiscal year, 7 analysts project revenue of $19.5M and an EPS of -$1.26. The firm beat EPS estimates in 3 of the last 4 quarters, and the next earnings date is November 11, 2026.

This page is an AI-written research summary of Immuneering Corporation (IMRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IMRX income statement, IMRX balance sheet, IMRX key metrics, IMRX analyst forecast, IMRX chart. See the IMRX stock overview for the latest quote and news.